Sera Prognostics Inc (NASDAQ:SERA) is set to release its Q4 2025 earnings on Mar 18, 2026. The consensus estimate for Q4 2025 revenue is $0.03 million, and the earnings are expected to come in at ...

Aligning Management Team given New Refined Commercial Focus on Institutions Starting with Recent Appointment of Board Member Zhenya Lindgardt as Interim President and CEO Engages Leading Strategy ...

Sera Prognostics, Inc. (SERA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Live audio of the webcast will be available online from the Investors page of the Company's website at www.sera.com. The webcast will be archived on the Investors page and will be available for one ...

Ongoing progress in engaging Medicaid plans in targeted states with prior PreTRM clinical study experience. Notable traction in two particular states with above-average premature birth rates, ...

Fewer health complications for newborns (20% reduction in odds of neonatal morbidity) A NICU day was saved for every 4.2 patients screened European Expert Commentary on the PRIME Trial Published in ...

SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ — Sera Prognostics, Inc., The Pregnancy Company ® (“Sera” or the “Company”) (Nasdaq: SERA), which focuses on improving maternal and neonatal health by ...

Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy ...

SALT LAKE CITY, Feb. 17, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy ...

56% and 32% fewer babies were born before 32 and 35 weeks, respectively 20% fewer babies admitted to the NICU Fewer health complications for newborns (20% reduction in odds of neonatal morbidity) A ...